HASLER HANS PETER
Transaction: 07/15/2026
BUY
Change
+25,000
Price
$1.68
Filing
07/17/2026
Type
BUY
Gain Therapeutics, Inc.
GANX • Biotechnology
$1.80
▼ -0.02 (-1.10%)
Current price
EarningsLatest report: Jun 30, 2026
WEAK PROFILEWeakConfidence: 70%
Quantitative profile — not an investment recommendation.
Quantitative profile — not an investment recommendation.Methodology
Analysis thesis: Weak historical ratio profile. The current evidence does not support a favorable risk/reward view.
Market Cap
$77.18M
Growth
-100.0%
Cash Flow
0/5
Trend
Negative
Evidence
Manageable debt level · 0.04Healthy liquidity · 6.63Negative growth trendWeak profitability
Financial data as of: Jun 30, 2026, 12:00 AM UTCLast earnings update: Jun 30, 2026, 12:00 AM UTCLast profile update: Aug 13, 2026, 12:20 PM UTC
Company Snapshot
Key valuation, quality, financial strength, momentum and analyst data.
Price$1.80
Change-1.10%
Shares Out42.88M
Market Cap$77.18M
Enterprise Value$64.37M
52W Range1.48 - 4.34
Beta0.19
P/E-3.84
P/B6.84
P/FCF-8.09
EV/EBITDA-3.35
EV/FCF-6.74
Price$1.80
Change-1.10%
Shares Out42.88M
Market Cap$77.18M
Enterprise Value$64.37M
52W Range1.48 - 4.34
Beta0.19
P/E-3.84
P/B6.84
P/FCF-8.09
EV/EBITDA-3.35
EV/FCF-6.74
Earnings Yield-26.05%
FCF Yield-12.37%
Dividend Yield0.00%
Gross Margin0.00%
Oper. Margin0.00%
Profit Margin0.00%
Debt/Eq0.04
Current Ratio6.63
Quick Ratio6.63
Revenue 5Y-100.00%
Target$7.80
Target Upside333.33%
Target Median$8.00
Target Range4.00 - 10.00
Volume584.54K
Avg Volume757.25K
EPS Surprise0.00
Investment DNA
How strong this company looks for long-term investors
35
out of 100
Business Quality
Margins, moat, returns
22/100
Financial Strength
Debt, cash, stability
76/100
Growth Potential
Revenue and expansion
20/100
Price Attractiveness
Cheap or expensive today
56/100
Why this score▼
Manageable debt level · 0.04Healthy liquidity · 6.63Negative growth trendWeak profitability
Analyst view
Analyst sentiment and price target
Analyst sentiment
Based on 8 analyst votes · 2026-09-05
94/100
Bullish
Bullish
7
Hold
1
Bearish
0
Price Target
2026-08-13
Low
$4.00
Mean
$7.80
Median
$8.00
High
$10.00
Insider Transactions
Recent executive and insider activity
Riley Jeffrey Scott
Transaction: 07/15/2026
BUY
Change
+25,000
Price
$1.68
Filing
07/17/2026
Type
BUY
Melincoff Gwen A
Transaction: 07/15/2026
BUY
Change
+25,000
Price
$1.68
Filing
07/17/2026
Type
BUY
| Insider | Type | Change | Price | Transaction | Filing |
|---|---|---|---|---|---|
| HASLER HANS PETER | BUY | +25,000 | $1.68 | 07/15/2026 | 07/17/2026 |
| Riley Jeffrey Scott | BUY | +25,000 | $1.68 | 07/15/2026 | 07/17/2026 |
| Melincoff Gwen A | BUY | +25,000 | $1.68 | 07/15/2026 | 07/17/2026 |
| Islam Khalid | BUY | +25,000 | $1.68 | 07/15/2026 | 07/17/2026 |
| Nicaise Claude | BUY | +25,000 | $1.68 | 07/15/2026 | 07/17/2026 |
| GOLDSTEIN DOV A MD | BUY | +25,000 | $1.68 | 07/15/2026 | 07/17/2026 |
| Fuggetta Gianluca | BUY | +50,000 | $1.86 | 03/24/2026 | 03/26/2026 |
| Mack Gene | BUY | +200,000 | $1.86 | 03/24/2026 | 03/26/2026 |
| Melincoff Gwen A | BUY | +15,000 | $1.79 | 06/24/2025 | 06/25/2025 |
| GOLDSTEIN DOV A MD | BUY | +15,000 | $1.79 | 06/24/2025 | 06/25/2025 |
| HASLER HANS PETER | BUY | +15,000 | $1.79 | 06/24/2025 | 06/25/2025 |
| RICHMAN ERIC I | BUY | +15,000 | $1.79 | 06/24/2025 | 06/25/2025 |
| Riley Jeffrey Scott | BUY | +15,000 | $1.79 | 06/24/2025 | 06/25/2025 |
| Nicaise Claude | BUY | +15,000 | $1.79 | 06/24/2025 | 06/25/2025 |
| Islam Khalid | BUY | +15,000 | $1.79 | 06/24/2025 | 06/25/2025 |
| Mack Gene | BUY | +200,000 | $2.29 | 03/20/2025 | 03/21/2025 |
| Fuggetta Gianluca | BUY | +50,000 | $2.29 | 03/20/2025 | 03/21/2025 |
| Mack Gene | BUY | +271,325 | $2.44 | 01/06/2025 | 01/07/2025 |
| Islam Khalid | BUY | +50,000 | $1.00 | 08/09/2024 | 08/12/2024 |
| Mack Gene | BUY | +14,400 | $1.01 | 08/09/2024 | 08/12/2024 |